How a heartburn medicine affects an experimental cancer drug
Treatments studied
This study tests how a common heartburn medicine (famotidine) affects the way your body processes an experimental cancer drug (taletrectinib). It's for healthy volunteers to see how the two drugs interact, which helps guide future dosing for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must be in good general health, with no major medical conditions.
- Your weight must be above 50 kg (about 110 lbs) and your body mass index (BMI) must be between 19 and 26.
- You need to agree to use effective birth control (or abstain from sex) during the study and for a time after it ends.
- You cannot be pregnant or breastfeeding.
- You must be willing to avoid certain foods (like grapefruit) and drinks (like alcohol and caffeine) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study checks if stomach acid medicine and another drug affect how the body handles a new investigational drug. It helps researchers understand dosing for future patients.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This study tests the drug taletrectinib in people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It is for those who have already tried the drug entrectinib and their cancer progressed. The study aims to see how well taletrectinib works in the real world.
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hear when a new Healthy Adult Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.